Skip to main content
Top
Published in: Pituitary 2/2009

01-06-2009

Alterations in body composition in acromegaly

Author: Laurence Katznelson

Published in: Pituitary | Issue 2/2009

Login to get access

Abstract

Acromegaly is a condition characterized by growth hormone (GH) and insulin-like growth factor-1 (IGF-1) hypersecretion, and is associated with boney overgrowth, and soft tissue abnormalities due to anabolic, lipolytic, and sodium retaining actions of GH. GH and IGF-1 excess is associated with alterations in body composition, including an increase in body water and lean body mass, and a reduction in body fat. Achievement of biochemical control of the disease results in a reduction in body water and fat-free mass, and an increase in body fat. BMD is generally increased in acromegaly, though the anabolic effect of GH excess on bone is reduced, if not negated, by the presence of hypogonadism, particularly with regard to the trabecular compartment. Further studies are necessary to determine the effect of long-term biochemical control on bone density in subjects with acromegaly.
Literature
1.
go back to reference Bengtsson BA, Brummer RJ, Eden S, Bosaeus I (1989) Body composition in acromegaly. Clin Endocrinol (Oxf) 30:121–130 MedlineCrossRef Bengtsson BA, Brummer RJ, Eden S, Bosaeus I (1989) Body composition in acromegaly. Clin Endocrinol (Oxf) 30:121–130 MedlineCrossRef
2.
go back to reference Gibney J, Wolthers T, Burt MG, Leung KC, Umpleby AM, Ho KK (2007) Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab 92:1479–1484 Medline. doi:10.1210/jc.2006-0664 PubMedCrossRef Gibney J, Wolthers T, Burt MG, Leung KC, Umpleby AM, Ho KK (2007) Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab 92:1479–1484 Medline. doi:10.​1210/​jc.​2006-0664 PubMedCrossRef
4.
go back to reference Rau H, Fischer H, Schmidt K, Lembcke B, Althoff PH (1991) Effect of bromocriptine withdrawal in acromegaly on body composition as assessed by bioelectrical impedance analysis. Acta Endocrinol (Copenh) 125:273–279 Medline Rau H, Fischer H, Schmidt K, Lembcke B, Althoff PH (1991) Effect of bromocriptine withdrawal in acromegaly on body composition as assessed by bioelectrical impedance analysis. Acta Endocrinol (Copenh) 125:273–279 Medline
7.
go back to reference Hansen TB, Gram J, Bjerre P, Hagen C, Bollerslev J (1994) Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clin Endocrinol (Oxf) 41:323–329 MedlineCrossRef Hansen TB, Gram J, Bjerre P, Hagen C, Bollerslev J (1994) Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clin Endocrinol (Oxf) 41:323–329 MedlineCrossRef
11.
go back to reference Brummer RJ, Lonn L, Bengtsson BA, Kvist H, Bosaeus I, Sjostrom L (1996) Comparison of different body composition models in acromegaly. Growth Regul 6:191–200 MedlinePubMed Brummer RJ, Lonn L, Bengtsson BA, Kvist H, Bosaeus I, Sjostrom L (1996) Comparison of different body composition models in acromegaly. Growth Regul 6:191–200 MedlinePubMed
12.
go back to reference Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479 Medline. doi:10.1210/jc.83.10.3476 PubMedCrossRef Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479 Medline. doi:10.​1210/​jc.​83.​10.​3476 PubMedCrossRef
14.
go back to reference Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E (2002) Serum leptin levels in acromegaly—a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 8:CR685–CR689 MedlinePubMed Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E (2002) Serum leptin levels in acromegaly—a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 8:CR685–CR689 MedlinePubMed
18.
go back to reference Damjanovic SS, Petakov MS, Raicevic S et al (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154 Medline. doi:10.1210/jc.85.1.147 PubMedCrossRef Damjanovic SS, Petakov MS, Raicevic S et al (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154 Medline. doi:10.​1210/​jc.​85.​1.​147 PubMedCrossRef
19.
go back to reference Baldelli R, Durante C, D’Amico E, Diacono F, Tamburrano G, Casanueva FF (2003) Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. J Endocrinol Invest 26:1219–1224 MedlinePubMed Baldelli R, Durante C, D’Amico E, Diacono F, Tamburrano G, Casanueva FF (2003) Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. J Endocrinol Invest 26:1219–1224 MedlinePubMed
22.
go back to reference Paramo C, Fluiters E, de la Fuente J, Andrade A, Garcia-Mayor RV (2001) Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Metabolism 50:1117–1121 Medline. doi:10.1053/meta.2001.24882 PubMedCrossRef Paramo C, Fluiters E, de la Fuente J, Andrade A, Garcia-Mayor RV (2001) Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Metabolism 50:1117–1121 Medline. doi:10.​1053/​meta.​2001.​24882 PubMedCrossRef
23.
26.
go back to reference Lam KS, Xu A, Tan KC, Wong LC, Tiu SC, Tam S (2004) Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J Clin Endocrinol Metab 89:5448–5453 Medline. doi:10.1210/jc.2003-032023 PubMedCrossRef Lam KS, Xu A, Tan KC, Wong LC, Tiu SC, Tam S (2004) Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J Clin Endocrinol Metab 89:5448–5453 Medline. doi:10.​1210/​jc.​2003-032023 PubMedCrossRef
27.
go back to reference Kotzmann H, Bernecker P, Hubsch P et al (1993) Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8:459–465 MedlinePubMedCrossRef Kotzmann H, Bernecker P, Hubsch P et al (1993) Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8:459–465 MedlinePubMedCrossRef
29.
go back to reference Wiesli P, Bernays R, Brandle M, Zwimpfer C, Seiler H, Zapf J, Spinas GA, Schmid C (2005) Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. Clin Chim Acta 352:175–181 Medline. doi:10.1016/j.cccn.2004.09.022 PubMedCrossRef Wiesli P, Bernays R, Brandle M, Zwimpfer C, Seiler H, Zapf J, Spinas GA, Schmid C (2005) Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. Clin Chim Acta 352:175–181 Medline. doi:10.​1016/​j.​cccn.​2004.​09.​022 PubMedCrossRef
30.
go back to reference Baum HB, Biller BM, Finkelstein JS et al (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883–890 MedlinePubMed Baum HB, Biller BM, Finkelstein JS et al (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883–890 MedlinePubMed
31.
go back to reference Hoffman AR, Kuntze JE, Baptista J et al (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056 Medline. doi:10.1210/jc.2003-030346 PubMedCrossRef Hoffman AR, Kuntze JE, Baptista J et al (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056 Medline. doi:10.​1210/​jc.​2003-030346 PubMedCrossRef
32.
33.
go back to reference Battezzati A, Benedini S, Fattorini A et al (2003) Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab 284:E823–E829 MedlinePubMed Battezzati A, Benedini S, Fattorini A et al (2003) Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab 284:E823–E829 MedlinePubMed
36.
go back to reference Landin K, Petruson B, Jakobsson KE, Bengtsson BA (1993) Skeletal muscle sodium and potassium changes after successful surgery in acromegaly: relation to body composition, blood glucose, plasma insulin and blood pressure. Acta Endocrinol (Copenh) 128:418–422 Medline Landin K, Petruson B, Jakobsson KE, Bengtsson BA (1993) Skeletal muscle sodium and potassium changes after successful surgery in acromegaly: relation to body composition, blood glucose, plasma insulin and blood pressure. Acta Endocrinol (Copenh) 128:418–422 Medline
38.
go back to reference Lucidi P, Laureti S, Santoni S et al (2000) Administration of recombinant human growth hormone on alternate days is sufficient to increase whole body protein synthesis and lipolysis in growth hormone deficient adults. Clin Endocrinol (Oxf) 52:173–179 Medline. doi:10.1046/j.1365-2265.2000.00910.x CrossRef Lucidi P, Laureti S, Santoni S et al (2000) Administration of recombinant human growth hormone on alternate days is sufficient to increase whole body protein synthesis and lipolysis in growth hormone deficient adults. Clin Endocrinol (Oxf) 52:173–179 Medline. doi:10.​1046/​j.​1365-2265.​2000.​00910.​x CrossRef
39.
go back to reference Lucidi P, Lauteri M, Laureti S et al (1998) A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 83:353–357 Medline. doi:10.1210/jc.83.2.353 PubMedCrossRef Lucidi P, Lauteri M, Laureti S et al (1998) A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 83:353–357 Medline. doi:10.​1210/​jc.​83.​2.​353 PubMedCrossRef
40.
go back to reference Mauras N, O’Brien KO, Welch S et al (2000) Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 85:1686–1694 Medline. doi:10.1210/jc.85.4.1686 PubMedCrossRef Mauras N, O’Brien KO, Welch S et al (2000) Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 85:1686–1694 Medline. doi:10.​1210/​jc.​85.​4.​1686 PubMedCrossRef
41.
go back to reference Nagulesparen M, Trickey R, Davies MJ, Jenkins JS (1976) Muscle changes in acromegaly. BMJ 2:914–915 MedlinePubMedCrossRef Nagulesparen M, Trickey R, Davies MJ, Jenkins JS (1976) Muscle changes in acromegaly. BMJ 2:914–915 MedlinePubMedCrossRef
42.
go back to reference Brumback RA, Barr CE (1983) Myopathy in acromegaly. A case study. Pathol Res Pract 177:41–46 MedlinePubMed Brumback RA, Barr CE (1983) Myopathy in acromegaly. A case study. Pathol Res Pract 177:41–46 MedlinePubMed
43.
go back to reference Pickett JB, Layzer RB, Levin SR, Scheider V, Campbell MJ, Sumner AJ (1975) Neuromuscular complications of acromegaly. Neurology 25:638–645 MedlinePubMed Pickett JB, Layzer RB, Levin SR, Scheider V, Campbell MJ, Sumner AJ (1975) Neuromuscular complications of acromegaly. Neurology 25:638–645 MedlinePubMed
44.
go back to reference Kassem M, Mosekilde L, Eriksen EF (1994) Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul 4:131–135 MedlinePubMed Kassem M, Mosekilde L, Eriksen EF (1994) Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul 4:131–135 MedlinePubMed
45.
46.
go back to reference Tauchmanova L, Di Somma C, Rusciano A, Lombardi G, Colao A (2007) The role for growth hormone in linking arthritis, osteoporosis, and body composition. J Endocrinol Invest 30:35–41 MedlinePubMed Tauchmanova L, Di Somma C, Rusciano A, Lombardi G, Colao A (2007) The role for growth hormone in linking arthritis, osteoporosis, and body composition. J Endocrinol Invest 30:35–41 MedlinePubMed
47.
go back to reference Colao A, Pivonello R, Scarpa R, Vallone G, Ruosi C, Lombardi G (2005) The acromegalic arthropathy. J Endocrinol Invest 28:24–31 MedlinePubMed Colao A, Pivonello R, Scarpa R, Vallone G, Ruosi C, Lombardi G (2005) The acromegalic arthropathy. J Endocrinol Invest 28:24–31 MedlinePubMed
49.
go back to reference Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B (2006) Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab 24:72–78 Medline. doi:10.1007/s00774-005-0649-9 PubMedCrossRef Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B (2006) Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab 24:72–78 Medline. doi:10.​1007/​s00774-005-0649-9 PubMedCrossRef
52.
go back to reference Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J (2006) Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155:709–715 Medline. doi:10.1530/eje.1.02285 PubMedCrossRef Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J (2006) Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155:709–715 Medline. doi:10.​1530/​eje.​1.​02285 PubMedCrossRef
53.
go back to reference Diamond T, Nery L, Posen S (1989) Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 111:567–573 MedlinePubMed Diamond T, Nery L, Posen S (1989) Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 111:567–573 MedlinePubMed
54.
go back to reference Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C (1996) Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 1:377–382 MedlinePubMed Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C (1996) Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 1:377–382 MedlinePubMed
55.
go back to reference Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650–5655 Medline. doi:10.1210/jc.2003-030772 PubMedCrossRef Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650–5655 Medline. doi:10.​1210/​jc.​2003-030772 PubMedCrossRef
57.
go back to reference Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F, Lucas T (1993) Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 52:419–421 Medline. doi:10.1007/BF00571329 PubMedCrossRef Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F, Lucas T (1993) Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 52:419–421 Medline. doi:10.​1007/​BF00571329 PubMedCrossRef
58.
go back to reference Piovesan A, Terzolo M, Reimondo G et al (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm Metab Res 26:234–237 MedlinePubMedCrossRef Piovesan A, Terzolo M, Reimondo G et al (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm Metab Res 26:234–237 MedlinePubMedCrossRef
Metadata
Title
Alterations in body composition in acromegaly
Author
Laurence Katznelson
Publication date
01-06-2009
Publisher
Springer US
Published in
Pituitary / Issue 2/2009
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-008-0104-8

Other articles of this Issue 2/2009

Pituitary 2/2009 Go to the issue